New antiobesity agents: Lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia)

Cardiology in Review

Volumn 22, Issue 1, 2014, Pages 43-50

  Shyh, Grace ^a   Cheng Lai, Angela ^b  

^a KINGSBROOK JEWISH MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Belviq; lorcaserin; obesity; phentermine topiramate ER; Qsymia; topiramate ER

Indexed keywords

LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; SEROTONIN 2 RECEPTOR;

CONSTIPATION; DIZZINESS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSGEUSIA; HUMAN; INSOMNIA; MENTAL DISEASE; NAUSEA; OBESITY; PARESTHESIA; PHASE 3 CLINICAL TRIAL (TOPIC); PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ANTI-OBESITY AGENTS; ANTICONVULSANTS; APPETITE DEPRESSANTS; BENZAZEPINES; BODY MASS INDEX; COMORBIDITY; DRUG APPROVAL; DRUG COMBINATIONS; FRUCTOSE; HUMANS; OBESITY; PHENTERMINE; SEROTONIN; SYMPATHOMIMETICS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84890525261     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000001     Document Type: Review

References (41)

1. World Health Organization. Obesity and overweight: Fact sheet (no.311). March 2013. Available at: Http://www.who.int/mediacentre/factsheets/fs311/ en/index.html. Accessed September 13, 2013
2. National Center for Health Statistics. National Health and Nutrition Examination Survey. Questionnaires, datasets, and related documentation. Available at: Http://www.cdc.gov/nchs/ nhanes/nhanes-questionnaires.htm. Accessed September 13, 2013
3. West Virginia State Department of Health and Human Resources. Obesity: Facts, figures, and guidelines. Available at: Http://www.wvdhhr.org/bph/oehp/ obesity/obesity1.pdf. Accessed September 13, 2013
4. Centers for Disease Control and Prevention. Vital Signs: State-specific obesity prevalence among adults-United States, 2009. Available at: Http://www.cdc. gov/mmwr/preview/mmwrhtml/mm59e0803a1.htm. Accessed April 9, 2013
5. Centers for Disease Control and Prevention (CDC). Defining overweight and obesity. Available at: Http://www.cdc.gov/obesity/defining.html. Accessed September 13, 2013
6. National Institutes of Health. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Pub. No. 98-4083. Bethesda, MD, September 1998. Available at: Http://www.nhlbi.nih.gov. Accessed September 13, 2013
7. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs. 2005;65:1391-1418
8. Li M, Cheung BM. Pharmacotherapy for obesity. Br J Clin Pharmacol. 2009;68:804-810
9. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: A quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26:262-273
10. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-588
11. Ioannides-Demos LL, Proietto J, Tonkin AM, et al. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf. 2006;29:277-302
12. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335:609-616
13. Jick H, Vasilakis C, Weinrauch LA, et al. A population-based study of appetite- suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719-724
14. Loke YK, Derry S, Pritchard Copley A. Appetite suppressants and valvular heart disease-A systematic review. BMC Clinical Pharmacol. 2002;2:article 6
15. Sachdev M, Miller WC, Ryan T, et al. Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-Analysis of observational studies. Am Heart J. 2002;144:1065-1073
16. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: A systematic review. Arch Intern Med. 2004;164:994-1003
17. James WP, Caterson ID, Coutinho W, et al SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905-917
18. Kang JG, Park CY. Anti-obesity drugs: A review about their effects and safety. Diabetes Metab J. 2012;36:13-25
19. Li Z, Maglione M, Tu W, et al. Meta-Analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546
20. Roth BL, Willins DL, Kristiansen K, et al. 5-Hydroxytryptamine2-family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): Where structure meets function. Pharmacol Ther. 1998;79:231-257
21. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131-181
22. Tecott LH, Sun LM, Akana SF, et al. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542-546
23. Smith SR, Weissman NJ, Anderson CM, et al Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256
24. Vivus Inc. VIVUS Announces Positive Results From Two Phase 3 Studies: Obese Patients on Qnexa Achieved Average Weight Loss up to 14.7% and Significant Improvement in Co-Morbidities: Results of EQUIP and CONQUER Phase 3 Studies Exceed FDA Benchmarks for Obesity Treatments, Demonstrate Positive Safety Profile. Available at: Http://ir.vivus.com/releasedetail. cfm?ReleaseID=407933. Accessed September 20, 2013
25. Kang JG, Park CY, Kang JH, et al. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffusecontrolled release for obesity. Diabetes Obes Metab. 2010;12:876-882
26. Thomsen WJ, Grottick AJ, Menzaghi F, et al. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: In vitro and in vivo pharmacological characterization. J Pharmacol Exp Ther. 2008;325:577-587
27. Smith BM, Smith JM, Tsai JH, et al. Discovery and structure-Activity relationship of (1R)-8-chloro-2,3,4,5-Tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. J Med Chem. 2008;51:305-313
28. Morgan M, Chen W, Anderson C, et al. Pharmacokinetic properties, metabolism and tolerability of lorcaserin in healthy volunteers. Paper presented at: Annual Meeting of the Obesity Society; October 3-7, 2008; Pheonix, AZ. Abstract 846-P
29. Belviq® Oral Tablets, Lorcaserin Hydrochloride Oral Tablets. Woodcliff Lake, NJ: Eisai Inc; 2012
30. Fidler MC, Sanchez M, Raether B, et al BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077
31. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study. Obesity (Silver Spring). 2012;20:1426-1436
32. Qsymia® [package insert]. Mountain View, CA: VIVUS, Inc; 2012
33. Richard D, Ferland J, Lalonde J, et al. Influence of topiramate in the regulation of energy balance. Nutrition. 2000;16:961-966
34. Richard D, Picard F, Lemieux C, et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord. 2002;26:344-353
35. Picard F, Deshaies Y, Lalonde J, et al. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res. 2000;8:656-663
36. Fujioka K, Lee MW. Pharmacologic treatment options for obesity: Current and potential medications. Nutr Clin Pract. 2007;22:50-54
37. Jordan J, Astrup A, Day WW. Effects of phentermine and extended-release topiramate alone and in combination on cardiovascular risk factors. Poster 697. 48th Annual Meeting of the European Association for the Study of Diabetes; October 1-5, 2011
38. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352
39. Garvey WT, Peterson CA, Troupin B. Weight loss with low-dose, controlledrelease phentermine/topiramate therapy improves glycaemic status and prevents progression to type 2 diabetes mellitus [abstract T5: P102]. 18th European Congress of Obesity; May 25-28, 2011; Istanbul, Turkey
40. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308
41. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330-342.